New Jersey-based pharmaceutical company Merck and South Korea's Alteogen (KOSDAQ:196170) partnered to develop an injectable version of Keytruda, but California-based biotechnology firm Halozyme Therapeutics claims the drug infringes on its patents.
A patent dispute could threaten Merck's strategy to extend Keytruda's market dominance beyond its IV version's patent expirations. Halozyme signaled a preference for licensing agreements but did not comment on litigation, the Wall Street Journal reported Wednesday.
Merck, which filed invalidity petitions against Halozyme's patents, insists the claims are baseless. The subcutaneous Keytruda, still in clinical trials, is expected to launch by early 2026, the report said.
Halozyme and Alteogen both develop hyaluronidase enzyme-based drug delivery technologies, competing for injectable drug formulations.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。